Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Engineered biodegradable polymeric nanoparticles injectable system of atorvastatin for improved therapeutic activity

Venkatraman R., B Narayanan VH., Nowakowski S., Nellinger S., Kluger P., Kopka B.

Animal Study on Face & Skin, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41361564
PMCID
PMC12796266
DOI
10.1038/s41598-025-31548-3

Abstract (original English)

Carrier-mediated drug delivery is one of the potential approaches employed to increase drug solubility and bioavailability. Atorvastatin (ATR), a HMG CoA reductase inhibitor, is a first-line medication prescribed for the treatment of hyperlipidemia and related cardiovascular diseases. The efficacy of ATR is highly limited due to its poor solubility and low oral bioavailability. In the present study, an injectable system of ATR-loaded polymeric nanoparticles was synthesized through the spray drying technique using chitosan polymer extracted in-house from a novel source of Portunus Sanguinolentus species shells. The effect of spray dryer nozzle diameter and polymer concentration on particle size, morphology, in vitro drug release, and ex vivo permeation was studied. The synthesized ATR-loaded chitosan particles were in the size range of 248.2 ± 17.58 nm to 329 ± 36.68 nm with homogeneous distribution. The average drug loading of all formulations was above 80%. The nozzle of 0.7 mm diameter produced smaller-sized particles with higher drug loading compared to the 1 mm diameter nozzle. Morphological analysis of the synthesized nanoparticles was performed using SEM, which revealed that particle size was increased linearly with increasing concentration of chitosan, with more flower-like structure deposition of polymer on the surface. The in vitro drug release and solubility study of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsPolymersChitosanDrug CarriersHydroxymethylglutaryl-CoA Reductase InhibitorsDrug Delivery SystemsParticle SizeSolubilityNanoparticlesDrug Liberation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research